The Peptide Report
SLU-PP-332 and Cardarine are both labeled 'exercise in a pill,' but they hit completely different molecular targets. Here's how the ERRα/β/γ pan-agonist stacks up against the PPARδ agonist on mechanism, endurance science, and safety.
Cardarine promised 'exercise in a pill' over a decade ago — but cancer signal concerns shelved it. Now SLU-PP-332, a next-generation ERR agonist, is rewriting the exercise mimetic playbook. Here's how they really compare.
A head-to-head breakdown of SLU-PP-332 (ERRα/β/γ pan-agonist) versus Cardarine (GW-501516, a PPARδ agonist) across mechanism, mitochondrial biogenesis, safety, and legal status. Discover which modern exercise mimetic actually delivers metabolic results in 2026.
A head-to-head comparison of SLU-PP-332 and Cardarine (GW-501516) — two leading exercise mimetics — across mechanism, metabolic effects, safety, and access. Here's how the doctor-formulated option stacks up against gray-market alternatives in 2026.
